NCT01445600 - ALTARGO(Retapamulin) PMS(Post-marketing Surveillance) | Biotech Hunter

Enrollment

3,612

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Skin Infections, Bacterial

Interventions

DRUG

ALTARGO(retapamulin)

Basically there is no treatment allocation. Subjects who would be administered of ALTARGO(retapamulin) at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.

Trial Locations (1)

138-736

GSK Investigational Site, Seoul